How Much Does Mounjaro Cost in South Dakota in 2026?

Retail Price of Mounjaro in South Dakota

The cash price for brand-name Mounjaro at South Dakota pharmacies holds steady at $1,023 per month regardless of dose strength. This matches the Eli Lilly wholesale acquisition cost that applies uniformly across the United States.

South Dakota's pharmacy market is concentrated. Most fills happen through major chains (Walgreens, CVS, Lewis Drug) and independent pharmacies clustered in Sioux Falls, Rapid City, and Aberdeen. Price variation between these outlets is minimal because Eli Lilly sets a single list price for all four pen configurations (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg). A single carton contains four prefilled pens, equaling one month of once-weekly injections.

Tirzepatide demonstrated significant glycemic and weight outcomes in the SURPASS-2 trial (N=1,879), where the 15 mg dose produced a mean HbA1c reduction of 2.58% and body weight loss of 12.4 kg at 40 weeks compared to semaglutide 1 mg 1. These results underpin the clinical rationale for prescribers choosing tirzepatide, but the cost barrier in South Dakota remains the primary obstacle for uninsured patients.

Without any discount mechanism, patients paying cash will spend $12,276 annually. That figure places Mounjaro among the most expensive chronic medications available at SD retail counters.

South Dakota Medicaid and Mounjaro Coverage

South Dakota Medicaid does not cover Mounjaro for weight management as of 2026. The state's preferred drug list restricts GLP-1 receptor agonist coverage to type 2 diabetes indications with prior authorization requirements.

For patients with a confirmed type 2 diabetes diagnosis, coverage remains inconsistent. South Dakota expanded Medicaid eligibility in 2023 following voter approval of Amendment D, adding roughly 50,000 new enrollees according to the South Dakota Department of Social Services. The expansion population generally receives benefits through managed care organizations that maintain their own formularies. Even for diabetes, step therapy requirements typically mandate trial and failure of metformin and a sulfonylurea before GLP-1 agents are authorized.

The practical reality: South Dakota Medicaid beneficiaries seeking tirzepatide for obesity or overweight will not receive plan coverage. Patients with type 2 diabetes may eventually access it, but only after documented failure of cheaper alternatives. This policy aligns with most state Medicaid programs nationwide. According to a 2024 KFF analysis, fewer than 15 state Medicaid programs cover any anti-obesity medication without diabetes 2.

Insurance Coverage for Mounjaro in South Dakota

Commercial insurance plans operating in South Dakota vary widely in tirzepatide coverage. The three largest carriers in the state (Avera Health Plans, Sanford Health Plan, and Dakota Care) each apply different formulary tiers and prior authorization criteria.

For type 2 diabetes, most commercial plans will cover Mounjaro at specialty or non-preferred brand tier, producing copays between $50 and $150 per month after deductible. Plans with high-deductible structures may expose patients to the full $1,023 list price until their annual deductible is met.

For weight management (off-label Mounjaro or on-label Zepbound), coverage is less predictable. Employer-sponsored plans in South Dakota with obesity benefits written into the plan document will typically cover tirzepatide. Self-funded employer plans, which cover the majority of commercially insured South Dakotans working for larger employers, set their own coverage rules independent of state insurance mandates.

South Dakota has no state mandate requiring insurers to cover anti-obesity medications. This contrasts with states like Connecticut and Maryland that have enacted parity legislation. Without a mandate, patients must rely on individual plan design. The FDA approved tirzepatide for chronic weight management under the brand name Zepbound in November 2023 3.

Patients should request a formulary exception or prior authorization through their prescriber if the initial claim is denied. Success rates for appeals vary, but the Endocrine Society's 2023 clinical practice guideline recommends pharmacotherapy for patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities 4, providing clinical justification for appeals.

Compounded Tirzepatide in South Dakota: Legality and Pricing

Compounded tirzepatide is legal and available in South Dakota through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidelines established by the Drug Quality and Security Act of 2013.

The average price for compounded tirzepatide in South Dakota runs approximately $249 per month. This represents a 76% savings compared to brand-name Mounjaro. Compounded versions are prepared as sterile injectable solutions, typically supplied in multi-dose vials requiring the patient to draw individual doses with insulin syringes.

Key distinctions between brand Mounjaro and compounded tirzepatide:

• Brand Mounjaro uses prefilled, single-use autoinjector pens. Compounded versions require manual vial-and-syringe preparation.
• Brand product undergoes FDA manufacturing oversight. Compounded preparations are not FDA-approved but are prepared under USP 797 sterile compounding standards.
• Compounded tirzepatide may use tirzepatide base or tirzepatide sodium salt, depending on the pharmacy's formulation.
• Lilly's patent protections remain active, but FDA shortage designation has permitted 503A compounding. The FDA's updated shortage list status should be verified before each fill.

South Dakota patients can access compounded tirzepatide from in-state 503A pharmacies or from out-of-state pharmacies licensed to ship into South Dakota. A valid prescription from a licensed prescriber (MD, DO, NP, or PA) is required in all cases.

The FDA noted in its October 2024 guidance that compounding of drugs on the shortage list is permitted, but pharmacies must cease compounding once a shortage is resolved. Patients should discuss supply continuity with their compounding pharmacy.

The Eli Lilly Savings Card in South Dakota

Eli Lilly's Mounjaro Savings Card program operates in South Dakota for commercially insured patients. The program reduces out-of-pocket costs to as low as $25 per monthly fill for eligible patients.

Eligibility requirements are straightforward. Patients must have commercial insurance (not Medicare, Medicaid, Tricare, or other government-funded plans), a valid Mounjaro prescription, and insurance that covers Mounjaro. The card covers up to $573 in copay costs per fill, with a maximum annual benefit of $3,400.

For patients whose insurance does not cover Mounjaro at all, Lilly also offers the Mounjaro Savings Card for cash-pay patients. This separate program reduces the monthly cost to $573 for patients paying entirely out of pocket. While still expensive, this represents a 44% reduction from the $1,023 list price.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, stated in 2023: "The cost of newer diabetes medications remains a significant barrier to access, particularly in rural states where formulary restrictions compound geographic challenges to specialty care" 5.

Enrollment is available online at the Lilly patient portal or through prescriber offices. The card is applied at the pharmacy counter as a secondary coverage. Processing takes 24 to 48 hours for initial activation.

Telehealth Access to Mounjaro in South Dakota

Telehealth prescribing of Mounjaro is fully legal in South Dakota. The state's telehealth parity law (SDCL 36-4-41.1) permits prescribers to initiate controlled and non-controlled medications via synchronous video visits without requiring an in-person examination first.

This is particularly relevant for South Dakota residents. The state's population density is 11.7 people per square mile. Many residents in western South Dakota live 60 or more miles from the nearest endocrinologist or obesity medicine specialist. Telehealth eliminates this geographic barrier entirely.

Multiple national telehealth platforms serve South Dakota patients for GLP-1 prescriptions. These platforms typically employ nurse practitioners or physicians licensed in South Dakota who can prescribe tirzepatide after a video consultation, lab review, and medical history assessment.

The telehealth workflow for obtaining Mounjaro in South Dakota:

1. Complete an online intake form with medical history, current medications, and weight-loss goals.
2. Submit recent lab work (metabolic panel, HbA1c if diabetic) or order labs through the platform.
3. Attend a synchronous video visit with a South Dakota-licensed prescriber.
4. Receive a prescription sent electronically to the pharmacy of your choice (retail or compounding).
5. Follow up monthly or quarterly depending on dose titration status.

According to the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks in participants without diabetes, compared to 2.4% with placebo 6. These outcomes drove significant telehealth demand nationally, including in South Dakota.

Cheapest Ways to Get Mounjaro in South Dakota

Six pricing pathways exist for South Dakota patients, ranked from least to most expensive per month:

1. Eli Lilly Savings Card with commercial insurance: ~$25/month. Best option for commercially insured patients whose plan covers Mounjaro.

2. Compounded tirzepatide from a 503A pharmacy: ~$249/month. Best option for uninsured or underinsured patients comfortable with vial-and-syringe administration.

3. Eli Lilly cash-pay savings card: ~$573/month. For patients without insurance coverage who prefer brand-name product.

4. Manufacturer patient assistance program (Lilly Cares): $0/month. Income-restricted (generally below 400% federal poverty level). Requires application and approval. Available for uninsured patients only.

5. Commercial insurance without savings card: $50-$150/month (after deductible, depending on tier).

6. Full retail cash price: $1,023/month. No discounts applied.

Patients should also check GoodRx, RxSaver, and similar pharmacy benefit aggregators, though discount pricing on Mounjaro specifically is limited because manufacturer contracts restrict below-WAC discounting at most chain pharmacies.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, noted: "The gap between clinical efficacy and financial accessibility remains the defining challenge of GLP-1 receptor agonist therapy in 2024 and beyond" 7.

Mounjaro Dosing and What to Expect

Tirzepatide is a dual GIP/GLP-1 receptor agonist administered as a once-weekly subcutaneous injection. The standard titration begins at 2.5 mg weekly for four weeks, then increases to 5 mg. Subsequent dose escalations occur in 2.5 mg increments every four weeks as tolerated, up to a maximum of 15 mg weekly.

This titration schedule means patients will spend their first month at the lowest dose regardless of their target. South Dakota patients should factor this into cost planning: the first month's cost is identical whether the eventual maintenance dose is 5 mg or 15 mg, since all dose strengths carry the same $1,023 price.

Common side effects reported in SURPASS trials include nausea (12-18% at lower doses, up to 24% at 15 mg), diarrhea, decreased appetite, and injection site reactions 1. Most gastrointestinal side effects are mild to moderate and diminish after the first 4 to 8 weeks of each dose level.

The prescribing information recommends against use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 3. Pancreatitis has been reported rarely. Patients with a history of pancreatitis should discuss risk-benefit with their prescriber before initiating therapy.

South Dakota-Specific Considerations

South Dakota's regulatory environment presents several unique factors for tirzepatide access:

Board of Pharmacy oversight. The South Dakota Board of Pharmacy licenses both retail and compounding pharmacies. 503A pharmacies operating within the state must maintain sterile compounding accreditation and undergo regular inspections. Out-of-state pharmacies shipping compounded products into South Dakota must hold a non-resident pharmacy license.

No state anti-obesity medication mandate. Unlike states that require commercial insurers to cover FDA-approved obesity treatments, South Dakota's insurance code contains no such mandate. Coverage depends entirely on individual plan design.

Rural access challenges. Specialty pharmacies capable of handling cold-chain biologics are concentrated in Sioux Falls and Rapid City. Patients in rural areas typically receive Mounjaro via mail-order pharmacy or direct shipment, adding 1 to 3 days to fill times.

Prescriber supply. South Dakota has approximately 2.1 physicians per 1,000 residents, below the national average of 2.6 per the AAMC 2023 workforce data. Telehealth platforms partially offset this shortage by connecting patients with out-of-state prescribers licensed in South Dakota through the Interstate Medical Licensure Compact, of which South Dakota is a member state 8.

Patients initiating tirzepatide in South Dakota should confirm their pharmacy stocks the prescribed dose strength before their appointment, request 90-day fills where insurance allows (reducing per-unit shipping costs for mail order), and establish a follow-up schedule of every 4 weeks during titration and every 12 weeks at maintenance dose.